Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
Click below to view clinical products for your clinical needs.
For In Vitro Diagnostic Use. For Emergency Use Authorization (EUA) Only | Rx Only
Click below to view Research Use Only (RUO) products for your molecular research needs.
For Research Use Only. Not for use in diagnostic procedures.
Need help finding the right product?
Find out more about our respiratory testing products and the benefits of molecular testing.
Get the facts on the clinical value of PCR testing for respiratory tract infections with this free educational infographic.
Respiratory Season Considerations for the Laboratory: The Clinical Utility and Use Cases for a PCR-Based Testing Approach.
This comprehensive review of viral, bacterial, fungal, and parasitic RTIs is divided into four chapters: Etiology and Pathophysiology, Clinical Practice, Testing Strategies and Initial Workup, and Public Health Surveillance.
Our mission is to prioritize scientific innovation in service of the health and well-being of everyone, everywhere. Access pricing is available to eligible customers.
Molecular testing for respiratory pathogens helps laboratories maximize sensitivity for common viruses, including SARS-CoV-2, flu, and RSV. As the pandemic continues to show signs of unpredictability and volatility, we expect SARS-CoV-2 and its variants to remain with us indefinitely. SARS-CoV-2 now joins the list of respiratory pathogens that pathologists will see in the lab, and influenza and COVID-19 share symptoms, making differential diagnosis even more challenging. With the overlap of symptoms, it is helpful for clinical and public health labs to be equipped with molecular tests that can detect genetic material from multiple respiratory viruses.
Multiplex testing assays allow laboratories to test for multiple infectious disease targets in a single reaction. This helps providers rule out multiple respiratory infections with one patient sample. Adoption of multiplex testing assays has grown over the last few years, most notably as a response to the SARS-CoV-2 pandemic.
A sample is sent to a lab where experts encourage organisms in the sample to multiply. Then they examine to identify the pathogen.
Nasal or throat swabs are mixed with liquid on a paper strip to return results within half an hour.
Genetic material from samples collected on swabs is amplified to detect genetic traces of a specific organism, even in early stages of infection.
Differentiating bacteria versus viral infection based on signs and symptoms alone can be challenging. Coughing and sneezing, fever, inflammation, vomiting, diarrhea, fatigue, and cramping can occur in various infections.
Lung-related | Other | |||
|
|
|
|
|
Diagnostic PCR (molecular) testing is considered the gold standard for pathogen detection and accuracy of results. The superior sensitivity of a molecular test can detect low pathogen loads. Molecular testing also has the benefit of scalability. Most lab-based PCR tests can accommodate 96 to 384 samples (including controls) simultaneously on a single plate.
Multiplex testing simultaneously differentiates respiratory diseases and helps identify cases of co-infection. Multiplex assay panels can go from two targets to dozens, making it an efficient technique.
The experience of molecular testing during the COVID-19 pandemic has experts looking at using the technology in other disease areas that are the subject of viral and bacterial infections.
Why accurate detection and identification of pathogens is at the core of infection treatment